Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03668600 · ClinicalTrials.gov registry record · Phase 3
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
A Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT03668600 is a Phase 3 study that was terminated before completion, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 230 participants.
The verdict
NCT03668600, a Phase 3 study, was terminated before completion, sponsored by Naurex, Inc, an affiliate of Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
Interventions
- DRUG Rapastinel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03668600
The ClinicalTrials.gov registry entry for NCT03668600 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapastinel is the first listed.
NCT03668600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03668600 about?
NCT03668600 is a clinical study titled "Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)". Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
What is the current status of trial NCT03668600?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2018-08-23. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT03668600?
The interventions under investigation include: Rapastinel (DRUG).
Who is sponsoring clinical trial NCT03668600?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.